Tyrosine kinase inhibitorPhase 3 trialInvestigational
Cabozantinib
How it works
Blocks the action of multiple tyrosine kinases, including MET, VEGFR2, and RET, which are involved in cell growth and division.
Cancer types
Efficacy
Cabozantinib has shown promise in treating ovarian cancer, with median progression-free survival of approximately 8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a Combination Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Rare Side Effect of Cancer Treatment: Pneumothorax in Renal Cell Carcinoma Patients | Lung Cancer | observational | — | Source → |
| Testing Cabozantinib and Atezolizumab for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing New Treatments for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Preventing Mucosal Melanoma Return After Surgery | Melanoma | phase-2 | — | Source → |
| Testing a New Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining Two Cancer Treatments Shows Promise in Advanced Melanoma | Melanoma | phase-1/2 | Among 20 patients treated in phase 2, the overall response rate was 45%, median progression-free survival was 6.6 months, and median overall survival was 29.5 months. | Source → |
| Cabozantinib Improves Progression-Free Survival in Advanced Neuroendocrine Tumors | Pancreatic Cancer | phase-3 | The median progression-free survival with cabozantinib was 8.4 months in patients with extrapancreatic neuroendocrine tumors and 13.8 months in patients with pancreatic neuroendocrine tumors. | Source → |
| Cabozantinib Linked to Higher Liver Damage Risk in Cancer Patients | Leukemia | meta-analysis | — | Source → |
| New Potential Treatment for Pancreatic Cancer Identified | Pancreatic Cancer | lab-study | — | Source → |
| Cabozantinib Shows Promise in Treating Melanoma Brain Metastasis | Melanoma | lab-study | — | Source → |
| Crizotinib and Cabozantinib Treatments Help Patient with Rare Lung Cancer Mutation | Lung Cancer | observational | The patient's disease achieved partial regression and progression-free survival lasted for 8 months, and overall survival was >12 months. | Source → |
| Cabozantinib Shows Promise in Treating Certain Cancers | Lung Cancer | phase-3 | Significant improvement in the primary endpoint (overall survival or PFS) were observed in patients on CAB in comparison with controls. | Source → |
| Targeted Delivery of Cancer-Fighting Nanoparticles | Prostate Cancer | animal-study | There was a 32-fold increase in mean fluorescent dye uptake following 3 days of cabozantinib/BSA-NP administration, relative to BSA-NP alone. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.